Projects and Grants per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Residency, University Of Chicago
1971
Residency, University Of Chicago
1967
Doctor of Medicine, Case Western Reserve University
1965
Fingerprint
Dive into the research topics where Robert Baumann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Projects & Grants
- 15 Finished
-
An Open-label Extension Phase of the Double-blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007(perampanel)Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures
Bensalem Owen, M. (PI), Baumann, R. (CoI) & Fakhoury, T. (Former PI)
5/8/09 → 10/31/14
Project: Research project
-
A Double-blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures
Bensalem Owen, M. (PI), Baumann, R. (CoI) & Fakhoury, T. (Former PI)
11/1/08 → 10/31/12
Project: Research project
-
Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome
Bensalem Owen, M. (PI), Baumann, R. (CoI), Fakhoury, T. (CoI) & Khan, G. (CoI)
7/1/08 → 3/31/09
Project: Research project
-
Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome
Bensalem Owen, M. (PI), Baumann, R. (CoI), Khan, G. (CoI) & Fakhoury, T. (Former CoI)
7/1/08 → 3/31/13
Project: Research project
-
An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy
Fakhoury, T. (PI), Baumann, R. (CoI) & Bensalem Owen, M. (CoI)
3/26/08 → 3/25/11
Project: Research project
-
David Clark
Baumann, R. J. & Swick, H. M., Jan 1 2021, Child Neurology: Its Origins, Founders, Growth and Evolution. p. 340-343 4 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
-
Evaluation of two fosphenytoin loading dose regimens and monitoring in infants and neonates less than six months of age
Bohannon, K. K., Leung, N., Cook, A. M., Autry, E., Gibson, J., Naranjo, V., Baumann, R. & Gardner, B., 2020, In: Journal of Pediatric Pharmacology and Therapeutics. 25, 7, p. 617-622 6 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Continuous Intravenous Valproate as Abortive Therapy for Pediatric Status Migrainosus
Zafar, M. S., Stewart, A. M., Toupin, D. N., Cook, A. M. & Baumann, R. J., 2018, In: Neurologist. 23, 2, p. 43-46 4 p.Research output: Contribution to journal › Article › peer-review
-
Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion
Cook, A. M., Zafar, M. S., Mathias, S., Stewart, A. M., Albuja, A. C., Bensalem-Owen, M., Kapoor, S. & Baumann, R. J., Jan 1 2016, In: CNS Drugs. 30, 1, p. 71-77 7 p.Research output: Contribution to journal › Article › peer-review
-
The place of generic modified-release formulations for epilepsy: Slow and steady
Baumann, R. J., Sep 20 2016, In: Neurology. 87, 12, p. 1305-1306 2 p.Research output: Contribution to journal › Comment/debate